SEC Form 4 · accession 0001192482-15-000357
Zynerba Pharmaceuticals, Inc. · ZYNE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Suzanne M. Hanlon
Officer — General Counsel
Period of report
Aug 4, 2015
Accepted (ET)
Aug 6, 2015 · 2:25 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001621443
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF1 | $14.00 | Aug 4, 2015 | A | 46,616 | A | — | Aug 4, 2025 | Common Stock | 46,616 | 46,616 | D |
Explanation of responses
- F1The stock option vests in sixteen equal quarterly installments beginning on November 4, 2015.